نتائج البحث - Renata Dega

  • يعرض 1 - 2 نتائج من 2
تنقيح النتائج
  1. 1
    Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

    Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial حسب Pippa Corrie, Andrea Marshall, Paul Nathan, Paul Lorigan, Martin Gore, S. Tahir, Guy Faust, Charles Kelly, Maria Marples, Sarah Danson, Ernest Marshall, Stephen Houston, Ruth Board, Ashita Waterston, Jenny Nobes, Mark Harries, Satish Kumar, Andrew Goodman, Angus Dalgleish, Agustín Martín-Clavijo, S. Westwell, Richard Casasola, David Chao, Anthony Maraveyas, Poulam M. Patel, Christian H. Ottensmeier, David Farrugia, Alison Humphreys, Bryony Eccles, Gareth T. Young, Emily Barker, Chloë Harman, M. Weiß, Kevin A. Myers, Anita Chhabra, Simon Rodwell, Janet Dunn, Mark R. Middleton, Paul Nathan, Paul Lorigan, Peter Dziewulski, Sonja Holikova, Udaiveer Panwar, Saad Tahir, Guy Faust, Anne Thomas, Pippa Corrie, Bhawna Sirohi, Charles Kelly, Mark R. Middleton, Maria Marples, Sarah Danson, J. Lester, Ernest Marshall, Mazhar Ajaz, Stephen Houston, Ruth Board, David Eaton, Ashita Waterston, Jenny Nobes, Suat Loo, Gill Gray, Helen Stubbings, Martin Gore, Mark Harries, Satish Kumar, Andrew Goodman, Angus Dalgleish, Agustín Martín-Clavijo, Jerry Marsden, S. Westwell, Richard Casasola, David Chao, Anthony Maraveyas, Ernest Marshall, Poulam M. Patel, Christian H. Ottensmeier, David Farrugia, Alison Humphreys, Bryony Eccles, Renata Dega, Chris Herbert, Christopher Price, Murray Brunt, Martin Scott-Brown, Joanna M. Hamilton, Richard Larry Hayward, John Smyth, Pamela Woodings, Neena Nayak, Lorna Burrows, Virginia Wolstenholme, John Wagstaff, M. Nicolson, Andrew Wilson, Clare Barlow, Christopher Scrase, T.J. Podd, Michael Gonzalez, John Stewart

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

    Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-infer... حسب Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert J. Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, R. McMenemin, Poulam M. Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter J. Selby, Fiona Collinson, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, M. Decatris, Carys Thomas, Joanna Gale, James J McAleer, Alison Clayton, Ekaterini Boleti, T. Geldart, Santhanam Sundar, J.F. Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Adil Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, R. Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, N Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, S. Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela C Scott, Mark Baxter, Anna Mullard, Pasquale F. Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry F. Taylor, Christos Mikropoulos, Martin Highley, D. Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, U. Barthakur, Erica Beaumont, Caroline Manetta, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: